Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation

Human Gene Therapy

Volumn 13, Issue 5, 2002, Pages 627-639

  Blank, Stephanie V ^a   Rubin, Stephen C ^a   Coukos, George ^a   Amin, Kunjlata M ^a   Albelda, Steven M ^a   Molnar Kimber, Katherine L ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G 207; R 3616; R 4009; R 7020; RECOMBINANT DNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER REGRESSION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOLYSIS; DNA MODIFICATION; DRUG CYTOTOXICITY; DRUG EFFECT; FEMALE; GENETIC ENGINEERING; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; LOW ENERGY RADIATION; MOUSE; NONHUMAN; NUDE MOUSE; RADIATION DOSE; SCID MOUSE; TUMOR GROWTH; TUMOR XENOGRAFT; UTERINE CERVIX CARCINOMA; VIRAL GENETICS; VIRUS MUTANT; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; BIOLOGICAL THERAPY; CELL DEATH; COMBINED MODALITY THERAPY; FEMALE; HELA CELLS; HERPESVIRUS 1, HUMAN; HUMANS; MICE; MICE, SCID; MUTATION; RADIATION DOSAGE; RADIOTHERAPY; UTERINE CERVICAL NEOPLASMS; VIRAL PROTEINS; VIRUS REPLICATION;

ANIMALIA; HUMAN HERPESVIRUS 1; MUS MUSCULUS; SIMPLEXVIRUS;

EID: 0036210311     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340252837224     Document Type: Article

References (67)

1. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: A new paradigm for destruction of therapeutically intractable tumors
2. Replication-competent nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors
3. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors
4. Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus
5. Epidemiology of uterine cervical cancer
6. The epidemiology of cervical cancer: Overview
7. Tumors arising in SCID mice share enhanced radiation sensitivity of SCID normal tissues
8. Phase 1 trial of R7020: A live attenuated recombinant herpes simplex virus (HSV) candidate vaccine
9. Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus
10. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a SCID mouse model of human malignant glioma
11. 1 34.5 a gene nonessential for growth in culture
12. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer
13. Application of recombinant herpes simplex virus-1 (HSV-1) for the treatment of malignancies outside the central nervous system
14. ICP34.5-deficient herpes simplex virus-1 kills ovarian cancer cells via non-apoptotic or p53-independent apoptotic death: Implications for chemotherapy-resistant disease
15. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy
16. Transcriptional activation of several heterologous promoters by the E6 protein of human papillomavirus type 16
17. Cancer statistics 2001
18. Herpes simplex virus type 2: A possible interaction with human papillomavirus types 16/18 in the development of invasive cervical cancer
19. Attenuated replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation of intracerebral injection in nonhuman primates
20. Radiotherapy for centrally recurrent cervical cancer of the vaginal stump following hysterectomy
21. Radiotherapy for centrally recurrent cervical cancer of the vaginal stump following hysterectomy
22. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional oncolytic herpes simplex virus type 1 mutant vectors in vivo
23. Role of the herpes simplex virus 1 internal repeat sequences in pathogenicity
24. Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer
25. Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant
26. Optimal management of locally advanced cervical carcinoma
27. Cisplatin radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma
28. Safety of intrapleurally administered recombinant adenovirus carrying herpes simplex thymidine kinase DNA followed by ganciclovir therapy in nonhuman primates
29. Use of a replication-restricted recombinant herpes virus to treat localized human malignancy
30. Expression of ribonucleotide reductase after ionizing radiation in human cervical carcinoma cells
31. Oncolytic therapy using a mutant type 1 herpes simplex virus and the role of the immune response
32. Effect of pre-existing anti-herpes immunity on the efficacy of herpes simplex virus therapy in a murine intraperitoneal tumor model
33. Radiotherapy for the treatment of locally recurrent cervical cancer
34. Herpes simplex virus type 1 deletion variant 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 171 between immediate early gene 1 and the "a" sequence
35. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir
36. Conditionally replicating herpes simplex virus mutant G207 for the treatment of malignant glioma: Results of a phase I trial
37. Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours - Evaluation of a potentially effective clinical therapy
38. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: Construction and evaluation in rodents
39. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus)
40. Treatment of malignant gliomas using ganciclovir-hypersensitive ribonucleotide reductase-deficient herpes simplex viral mutant
41. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas
42. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer
43. Tumor size irradiation dose and long-term outcome of carcinoma of uterine cervix
44. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix
45. Characterization of a viable noninverting herpes simplex virus 1 genome derived by insertion and deletion of sequences at the junction of components L and S
46. Relationships between the cytotoxic effects of restriction endonucleases and radiation on mammalian cells
47. Toxicity evaluation of replication-competen t herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma
48. Herpes simplex 1716 - An ICP 34.5 mutant - Is severely replication restricted in human skin xenografts in vivo
49. Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant
50. The function of herpes simplex virus genes: A primer for genetic engineering of novel vectors
51. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer
52. Gene therapy for cancer: What have we done and where are we going?
53. Replicating vectors for gene therapy of cancer: Risks limitations and prospects
54. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia
55. Cytotoxicity apoptosis and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation
56. Attenuated replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation in mice
57. Adjuvant therapy after primary surgery for stage I-IIA carcinoma of the cervix
58. Treatment of human breast cancer in a brain metastatic model by G207 a replication competent multimutated herpes simplex virus 1
59. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity
60. Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer
61. Prognostic factors for local and distant recurrence in stage I and II cervical carcinoma
62. A radiobiological comparison of human tumor soft-agar clonogenic assays
63. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative paraaortic lymph nodes: A gynecologic oncology group and Southwest oncology group study
64. Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector
65. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma
66. Prognosis-predicting system based on factors related to survival of cervical carcinoma
67. High-efficiency stable gene transfer of adenovirus into mammalian cells using ionizing radiation